Krka has announced the launch of Tuloxxin, billed as an affordable solution for bovine respiratory disease (BRD) triggered by Mannheimia haemolytica, Histophilus somni, Pasterella multocida and Mycoplasma bovis.

Tuloxxin contains Tulathromycin and Krka says it is based on the same formulation as the market leader.

In cattle Tuloxxin is administered using a single subcutaneous injection; in sheep Tuloxxin is licensed for use in the treatment of foot rot associated with Dichelobacter nodosus and also in pigs for swine respiratory disease (SRD) administered via a single intra-muscular injection. Krka says it is fast-acting, and that the one dose formulation supports compliance and so reduces stress to herds and flocks.

Charlotte Read, Key Account Manager – Farm, at Krka, said: "Whenever Krka launches a generic product, we aim to add some extra value to it. Tuloxxin is a good example. It is based on a tried and trusted active and delivers efficacy; with formulation and delivery method technology at exceptional value. We hope its launch will support vets in their appropriate choice of antibiotic for specific cases. In so doing, they will be protecting their clients’ cattle and profitability while also playing their part in reducing antimicrobial use.”

Tuloxxin is available now from all wholesalers.

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.